Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Measurable relapsed or refractory myeloma as defined by the International Myeloma Working Group (IMWG) Consensus Criteria following treatment with at least 3 lines of therapy including with both a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or progressive myeloma that is refractory to a regimen containing both a PI and an IMiD.~2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~3. Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:~   * Absolute neutrophil count (ANC) ≥ 1,000/µL~  * Platelet count ≥ 75,000/µL~  * Absolute lymphocyte count ≥ 100/µL~  * Creatinine clearance above limits set in the protocol for each cohort~  * Normal cardiac function as assessed by electrocardiogram (ECG) and echocardiogram~  * Baseline oxygen saturation \> 92% on room air and no clinically significant pleural effusion~Key Exclusion Criteria:~1. Plasma cell leukemia~2. Non-secretory multiple myeloma~3. History of Central nervous system (CNS) involvement by multiple myeloma~4. Prior CAR therapy or other genetically modified T cells~5. Inadequate washout from prior therapy~6. Autologous stem cell transplant within 6 weeks before enrollment or any history of allogenic transplant~7. History of active autoimmune disease~8. History of deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within 6 months before enrollment~9. Recent history of other (non multiple myeloma) cancer~10. Active viral, fungal, bacterial or other infection~Note: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation: 3 x 10^7 KITE-585 (Type: EXPERIMENTAL): Participants with relapsed/refractory multiple myeloma (RRMM), will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day intravenous (IV) infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\^7 autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
- Dose Escalation: 1 x 10^8 KITE-585 (Type: EXPERIMENTAL): Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\^8 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
- Dose Escalation: 3 x 10^8 KITE-585 (Type: EXPERIMENTAL): Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\^8 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
- Dose Escalation: 1 x 10^9 KITE-585 (Type: EXPERIMENTAL): Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\^9 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
- Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 (Type: EXPERIMENTAL): RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min \[Grade 2 chronic kidney disease\]) will receive a conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 24 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a tolerable dose of 3 x 10\^7 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants then had a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).